載入...
(86/90)Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics
Pancreatic cancer is highly aggressive, with a median survival time of less than 6 months and a 5-year overall survival rate of around 7%. The poor prognosis of PaCa is largely due to its advanced stage at diagnosis and the lack of efficient therapeutic options. Thus, the development of an efficient...
Na minha lista:
| 發表在: | Mol Pharm |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7265990/ https://ncbi.nlm.nih.gov/pubmed/32202792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.0c00127 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|